The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

Philippe Armand, Dana-Farber Cancer Institute
Haesook T. Kim, Dana-Farber Cancer Institute
Marie-Michele Sainvil, Dana-Farber Cancer Institute
Paulina B. Lange, Dana-Farber Cancer Institute
Angela A. Giardino, Brigham & Womens Hosp
Veronika Bachanova, University of Minnesota
Steven M. Devine, Ohio State University
Edmund Waller, Emory University
Neera Jagirdar, Emory University
Alex F. Herrera, City of Hope Cancer Center

Only first 10 authors above; see publication for full author list.

Journal Title: British Journal of Haematology
Volume: Volume 173, Number 1
Publisher: Wiley: 12 months | 2016-04-01, Pages 96-104
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1111/bjh.13931
Permanent URL: https://pid.emory.edu/ark:/25593/rzsg0

Final published version: http://dx.doi.org/10.1111/bjh.13931

Copyright information:
© 2016 John Wiley & Sons Ltd

Accessed February 9, 2019 7:07 PM EST
The Addition of Sirolimus to the Graft-Versus-Host Disease Prophylaxis Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation for Lymphoma: A Multicentre Randomized Trial

Philippe Armand, MD, PhD,1 Haesook T. Kim, PhD,2 Marie-Michele Sainvil,1 Paulina B. Lange,1 Angela A. Giardino, MD,3 Veronika Bachanova, MD,4 Steven M. Devine, MD,5 Edmund K. Waller, MD, PhD,6 Neera Jagirdar, MD,6 Alex F. Herrera, M.D.,7 Corey Cutler, M.D.,1 Vincent T. Ho, M.D.,1 John Koreth, M.B.B.S., D.Phil.,1 Edwin P. Alyea, M.D.,1,6 Steven L. McAfee, MD,5 Robert J. Soiffer, M.D.,1, Yi-Bin Chen, MD,8 and Joseph H. Antin, M.D.,1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA
2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA
3Department of Radiology, Brigham and Women's Hospital, Boston MA
4Department of Medical Oncology, University of Minnesota, Minneapolis MN
5Department of Medicine, The Ohio State University Comprehensive Cancer Center Ohio State University, Columbus, OH
6Department of Hematology/Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
7City of Hope Cancer Center, Duarte CA

Corresponding author: Philippe Armand, MD, PhD. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, 617-632-2305 (ph); 617-632-4422 (fax), parmand@partners.org.

AUTHOR CONTRIBUTIONS
P.A. designed the research, analysed the data and wrote the paper.
H.T.K. designed the research, analysed the data and edited the paper.
M.M.S. collected data and edited the paper.
P.B.L. collected data and edited the paper.
A.A.G. analysed data and edited the paper.
V.B. designed the research, collected data and edited the paper.
S.M.D. designed the research, collected data and edited the paper.
E.K.W. designed the research, collected data and edited the paper.
N.J. collected data and edited the paper.
A.H. collected data and edited the paper.
C.C. collected data and edited the paper.
V.T.H. collected data and edited the paper.
J.K. collected data and edited the paper.
E.P.A. collected data and edited the paper.
S.L.M. collected data and edited the paper.
R.J.S. designed the research, collected data and edited the paper.
Y.-B.C. designed the research, collected data and edited the paper.
J.H.A. designed the research, collected data and edited the paper.

The interim analysis of this study was presented at an oral session of the American Society of Hematology meeting in December 2013 in New Orleans, LA.

CONFLICT OF INTEREST DISCLOSURES
The authors have no relevant conflicts of interest to disclose.
Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Boston MA.

Abstract

Inhibition of the mechanistic target of rapamycin (serine/threonine kinase) (mTOR) pathway has clinical activity in lymphoma. The mTOR inhibitor sirolimus has been used in the prevention and treatment of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A retrospective study suggested that patients with lymphoma undergoing reduced intensity conditioning (RIC) HSCT who received sirolimus as part of their GVHD prophylaxis regimen had a lower rate of relapse. We therefore performed a multicentre randomized trial comparing tacrolimus, sirolimus and methotrexate to standard regimens in adult patients undergoing RIC HSCT for lymphoma in order to assess the possible benefit of sirolimus on HSCT outcome. 139 patients were randomized. There was no difference overall in 2-year overall survival, progression-free survival, relapse, non-relapse mortality or chronic GVHD. However, the sirolimus-containing arm had a significantly lower incidence of grade II-i.v. acute GVHD (9% versus 25%, \( p = 0.015 \)), which was more marked for unrelated donor grafts. In conclusion, the addition of sirolimus for GVHD prophylaxis in RIC HSCT is associated with no increased overall toxicity and a lower risk of acute GVHD, although it does not improve survival; this regimen is an acceptable option for GVHD prevention in RIC HSCT. This trial is registered at clinicaltrials.gov (NCT00928018).

Keywords

clinical trials; lymphomas; stem cell transplantation; GVHD

INTRODUCTION

The mTOR [mechanistic target of rapamycin (serine/threonine kinase)] inhibitor sirolimus has been used extensively for the prevention and treatment of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) (Alyea et al 2008, Antin et al 2003, Benito et al 2001, Couriel et al 2005, Cutler et al 2004, Cutler et al 2007, Furlong et al 2008, Ho et al 2009, Johnston et al 2005, Jurado et al 2007, Perez-Simon et al 2013, Rodriguez et al 2010, Rosenbeck et al 2011). A randomized phase II trial in patients receiving mostly myeloablative HSCT suggested a benefit to tacrolimus/sirolimus (Tac/Sir) over tacrolimus/methotrexate (Tax/Mtx) (Pidala et al 2012) in terms of acute GVHD prevention; however, a phase III randomized trial (Blood and Marrow Transplantation Clinical Trial Network [BMT CTN] 0402) comparing those 2 regimens in patients undergoing myeloablative HSCT from matched related donors for acute myeloid leukaemia, myelodysplastic syndromes or acute lymphoblastic leukaemia (ALL) showed no significant difference in acute GVHD (aGVHD)-free survival (Cutler et al 2012), despite a trend towards lower rates of aGVHD. Of note, this trial did not enrol patients receiving unrelated donor grafts, who are at higher risk of aGVHD, and methotrexate was omitted from the experimental arm. Another randomized trial (Children's Oncology Group [COG] ASCT0431) showed that sirolimus, when added to tacrolimus and methotrexate, reduced the risk of grade II-i.v. acute GVHD in children with ALL receiving a myeloablative HSCT.
from related, unrelated or cord blood donors, but at the expense of an increase in veno-
occlusive disease (VOD) and thrombotic microangiopathy (TMA) (Pulsipher, et al 2014). A
more recent randomized phase 2 study in patients receiving reduced intensity conditioning
(RIC) HSCT from unrelated donors suggested a decrease in acute GVHD when sirolimus
was added to tacrolimus and mycophenolate mofetil (Kornblit, et al 2014). In parallel, other
mTOR inhibitors (everolimus and temsirolimus) have demonstrated clinical activity in a
variety of lymphoma histologies, including non-Hodgkin and Hodgkin lymphoma (NHL and
conducted a retrospective study at our institution which suggested that patients with
lymphoma who received a sirolimus-containing GVHD prophylaxis regimen had a lower
risk of relapse and a lower risk of grade II-i.v. aGVHD (Armand, et al 2008); in this study
the relapse benefit was only apparent in patients who received a reduced intensity
conditioning (RIC) HSCT. A subsequent report also suggested favourable outcomes in
patients with lymphoid malignancies receiving this regimen (Ceberio, et al 2015). Therefore,
we prospectively tested the putative benefit of the addition of sirolimus to the GVHD
prophylaxis regimen in a multicentre randomized clinical trial in patients with lymphoma
undergoing RIC HSCT; this is the first phase III randomized trial of sirolimus in RIC
transplantation, and the first phase III trial to test the addition of sirolimus to methotrexate
rather than the replacement of methotrexate by sirolimus.

METHODS

Patients and Centres

This phase III, open-label, randomized clinical trial enrolled patients at 5 transplant centres
in the United States. Eligible participants were adults aged 18-72 years with any lymphoma
type, including HL and B- or T-cell NHL, with the exception of Burkitt lymphoma or
diffuse large B cell lymphoma (DLBCL) known to harbour a MYC translocation. Patients
had to have a matched (8/8) related (MRD) or unrelated (MUD) donor. Exclusion criteria
included prior allogeneic HSCT, Karnofsky performance status (KPS) ≤80%, uncontrolled
infection, creatinine ≥176.8 μmol/l, total bilirubin ≥34.2 μmol/l, alanine aminotransferase
or aspartate aminotransferase ≥3 times upper limit of normal, left ventricular ejection
fraction < 30%, cholesterol > 12.95 mmol/l or triglycerides > 5.65 mmol/l despite
appropriate treatment, and seropositivity for i.v. human immunodeficiency virus. All patients
signed informed consent; the study was registered on clinicaltrials.gov (NCT00928018),
monitored by an independent Data and Safety Monitoring Board (DSMB), and conducted in
accordance with the principles of the Declaration of Helsinki. Patients were enrolled
between June 2009 and November 2012.

Transplantation

Because of the multicentre nature of this study, each centre could select at the outset one of
two conditioning regimens. All centres except one used Flu/Bu (fludarabine 30 mg/m² i.v. +
busulfan 0.8 mg/kg i.v. daily given on days -5 to -2); patients transplanted at the University
of Minnesota (UMN) received their standard RIC regimen of Flu/Cy/TBI (fludarabine 30
mg/m² i.v. on days -6 to -2, cyclophosphamide 50 mg/kg i.v. on day -6, and total body
irradiation in a single 200 cGy fraction on day -1). All patients received filgrastim-mobilized peripheral blood (PB) grafts at a target dose of 2-10 × 10^6 CD34+ cells/kg recipient weight. Supportive care was given per institutional guidelines.

**GVHD Prophylaxis**

Patients were randomized 0-5 days prior to the start of conditioning to the experimental arm (Arm A) or the control arm (Arm B). Randomization was 1:1 and stratified by general histological group, centre and donor type, using a permuted block algorithm within strata. All patients on Arm A received tacrolimus (0.05 mg/kg orally b.i.d. starting day -3, with a goal trough level of 5-10 ng/ml), sirolimus (12 mg orally on day -3, then 4 mg daily, with a goal trough level of 5-12 ng/ml) and low-dose methotrexate (5 mg/m^2 i.v. days 1, 3, and 6) (Tac/Sir/Mtx). Each centre could select one of two control GVHD prophylaxis regimens. All centres except one used tacrolimus (with the same dose and trough goal as on Arm A) + low-dose methotrexate (as on Arm A with an extra dose on day 11 for recipients of an unrelated donor graft) (Tac/Mtx, Arm B1). Patients transplanted at UMN received their standard RIC GVHD regimen of ciclosporin (6 mg/kg b.i.d. starting day -3, with a goal trough level of 200-400 ng/ml) + mycophenolate mofetil (3 g daily orally in 2-3 divided doses, starting on day 3) (CSA/MMF, Arm B2). Tapering was at the discretion of the treating clinician, but the study recommended that the calcineurin inhibitor be tapered between days 100 and 180, sirolimus between days 180 and 360, and MMF (for patients on Arm B2) stopped at day 30.

**Statistical Analysis**

Baseline characteristics were compared between the two arms using Wilcoxon rank sum test for continuous variables and Fisher’s exact test for categorical variables. The primary endpoint of the study was 2-year overall survival (OS), defined as the time from randomization to death from any cause. Secondary endpoints included toxicity, progression-free survival at 2 years (PFS), defined as the time from randomization to disease relapse, progression or death from any cause, whichever occurred first, cumulative incidence of relapse/progression (CIR) and non-relapse mortality (NRM), 6-month cumulative incidence of grade II-IV and grade III-IV aGVHD, and 2-year cumulative incidence of chronic GVHD (cGVHD). GVHD was defined according to standard criteria (Przepiorka, et al 1995). Other endpoints included a comparison of arm A with arm B1 (Tac/Mtx), and comparisons of outcomes within each broad histological group (indolent B-cell NHL, aggressive B-NHL including mantle cell lymphoma [MCL], T-cell NHL and HL). The study was powered to detect a 20% difference in 2-year OS between the 2 arms, based on the results of our retrospective study (Armand, et al 2008). With 136 eligible patients, the study had 81% power at a one-sided significance level of 0.025. Because patients would be randomized within the 5 days preceding the beginning of conditioning, in order to account for the possibility that a randomized patient might not actually proceed to transplantation, the accrual goal was set to 140. Two interim analyses were planned with stopping rules in favour of the alternative hypothesis using truncated O’Brien-Fleming boundaries (Freidlin, et al 1999), and with stopping rule for futility using repeated confidence interval (RCI) methodology similar to that described by Jennison and Turnbull (1984). The primary analysis was an intention-to-treat analysis with all randomized patients. OS and PFS were
calculated using the Kaplan-Meier method, and the stratified log-rank test was used for comparisons of the arms. CIR, NRM and GVHD were calculated in the competing risks framework and compared using Gray test (Gray 1988). Cox proportional hazards model was used for multivariate analyses. All calculations were performed using SAS 9.3 (SAS Institute Inc, Cary, NC), and R version 2.13 (R Foundation for Statistical Computing, Vienna Austria).

RESULTS

Patients

A total of 140 patients were randomized; 67 to Arm A and 73 to Arm B. One patient was registered and randomized to Arm A, but had transplantation delayed because of liver dysfunction. He was later re-registered and randomized on Arm B, and analysed as such. Therefore, 139 individual patients were treated and analysed. One patient randomized to Arm A withdrew consent for treatment and was treated as on Arm B, but analysed in Arm A based on intent-to-treat. Therefore, 65 of the 67 patients on Arm A received treatment per protocol, as did all 73 patients on Arm B (69 on Arm B1 and 4 on Arm B2). One hundred and thirty-two patients received Flu/Bu conditioning, while the remaining 7 received Flu/Cy/TBI. Patient characteristics are shown in Table I. Median age was 57 (range, 23-70) years; 88% were transplanted with chemosensitive disease; 47% had previously received an autologous stem cell transplant; 40% received a graft from an MRD and 60% from a MUD.

Toxicity

Adverse events were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). The study required reporting of all grade 2 adverse events (AEs) that were unexpected and related to study treatment, as well as any grade 3 or above event whether related or not. Given the difficulty of attributing AEs on this study, since any infectious or GVHD-related toxicity could be attributed to the GVHD prophylaxis regimen, we considered and compared all AEs regardless of attribution. As shown in Table II, there was no excess grade 3 or 4 toxicity in the experimental arm. In fact, the number of grade 3-4 events was lower on Arm A than on Arm B (128 versus 194). There was no reported VOD on either arm. There was no excess risk of severe myelosuppression or hyperlipidaemia on Arm A; there was as expected an increased risk of grade 3-4 TMA, with 15 events (including events reported as renal failure or haemolysis) versus 8 on Arm B (4 versus 2 for grade 4 events); conversely, the number of grade 3-4 infections was lower in Arm A (9 versus 18).

Graft-versus-host disease

As shown in Figure 1A, the 6-month cumulative incidence of grade II-IV aGVHD on Arm A was 9% (95% confidence interval [95CI] 4-18), which was significantly lower than on Arm B (25%, 95CI 15-35, \( p=0.015 \)). There was no difference in grade III-IV aGVHD (3% versus 4%, \( p=0.7 \), Figure 1B), or in the 2-year incidence of cGVHD (59% versus 63%, \( p=0.5 \), Figure 1D). The difference in aGVHD was similar in a comparison of Arm A with Arm B1 (Tac/Mtx group; not shown). In additional analyses not pre-specified per protocol,
we compared the incidence of aGVHD among patients receiving MRD grafts (4% on Arm A versus 14% on Arm B, $p=0.2$) and among those receiving MUD grafts (13% versus 32%, $p=0.038$) (Figure 1C). We also compared incidences of aGVHD using the International Bone Marrow Transplant Registry grading (Rowlings, et al 1997); the incidence of grade B-D aGVHD was 12% on Arm A versus 34% on Arm B ($p=0.002$); that of grade C-D was 8% versus 16% ($p=0.11$). We also analysed post hoc the differences in aGVHD by organ involved, for exploratory purposes, and found that the difference in aGVHD was significant only for skin and for liver disease, but not for gut disease. For cGVHD, there was no difference between arms for either MRD or MUD groups, and no difference in extensive disease (not shown). The proportion of patients who received systemic corticosteroids in the first year after HSCT was 47% on Arm A versus 60% on Arm B ($p=0.13$).

**Survival**

There was no difference between the study arms in OS, PFS, CIR or NRM (Figure 2). The 2-year OS was 70% (95CI 57-79) on Arm A versus 68% (95CI 57-78) on Arm B ($p=0.7$). The 2-year PFS was 61% (95CI 48-71) versus 58% (95CI 45-68) ($p=0.9$); the 2-year CIR 26% (95CI 16-37) versus 30% (95CI 20-41) ($p=0.6$); and the 2-year NRM 14% (95CI 7-23) versus 12% (95CI 6-21) ($p=0.6$). We also examined, in protocol-specified analyses, the impact of GVHD prophylaxis on OS and PFS within each histological subgroup. Given the small number of patients within each group, we considered indolent histologies (indolent B-cell NHL, chronic lymphocytic leukaemia and HL) together in one group (indolent group), and aggressive histologies (aggressive B-cell NHL, MCL and T-cell NHL) in another (aggressive group). Within the indolent group, the 2-year OS on Arm A was 82% versus 63% on arm B ($p=0.082$) (Figure 2E); the corresponding PFS were 71% and 53%, respectively ($p=0.13$). Within the aggressive group, the 2-year OS on Arm A was 54% versus 76% on arm B ($p=0.077$) (Figure 2F); the corresponding PFS were 46% and 64%, respectively ($p=0.24$). Based on this apparent difference, and since the 2 subgroups remained heterogeneous with respect to disease and patient risk, we conducted ad hoc multivariate analyses within each subgroup, including treatment assignment (arm A versus arm B), disease status at HSCT (complete remission [CR] versus partial remission [PR] versus advanced), age (< versus ≥ 60 years) and donor type (MRD versus MUD). In those models, the hazard ratio (HR) for mortality associated with Arm A (versus Arm B) in the indolent group was 0.4 (95CI 0.2-1.0, $p=0.056$), and in the aggressive group it was 2.3 (95CI 0.9-5.7, $p=0.075$); the corresponding HRs for PFS were 0.5 (95CI 0.2-1.1, $p=0.096$) in the indolent group and 1.7 (95CI 0.8-3.8, $p=0.17$) in the aggressive group. The effect of sirolimus on acute and chronic GVHD incidences was similar in the indolent and the aggressive groups. In the indolent group, the 2-year CIR was 21% on Arm A and 33% on Arm B ($p=0.4$), while 2-year NRM was 8% and 15% ($p=0.5$), respectively; in the aggressive group, the 2-year CIR was 32% on Arm A and 27% on Arm B ($p=0.9$), and NRM 21% and 9% ($p=0.2$) respectively.

**DISCUSSION**

The hypothesis for this trial was that the mTOR inhibitor sirolimus could exert a double benefit after HSCT: reduce the incidence of acute GVHD and the risk of lymphoma relapse.
However, the trial showed no evidence of a benefit for relapse prevention overall, in contrast to our previous retrospective study (Armand, et al 2008). It is possible that the decreased risk of relapse in the retrospective study was related to unmeasured confounders, especially as many patients in the sirolimus group had been treated in later years and often on clinical trials, both of which have been associated with improved outcomes (Armand, et al 2012, Gooley, et al 2010). However, it is also possible that the benefit of sirolimus on relapse prevention is histology-specific. In fact, there was a strong trend for an improvement in OS with sirolimus addition in patients with indolent histologies. Conversely, for patients with aggressive histologies, the addition of sirolimus appeared to be associated with a trend to a worse OS, which did not appear to be related to a differential effect on GVHD incidence. In the indolent group, there was a trend towards a lower relapse risk, but there was no such trend in the aggressive group. In general, mTOR inhibitors have shown therapeutic activity across both indolent and aggressive lymphoma histologies, so we cannot explain this finding based on our present understanding.

This trial did demonstrate a significant reduction in grade 2-4 aGVHD with the addition of sirolimus, which was a secondary endpoint. This benefit in terms of aGVHD prevention with the addition of sirolimus was apparent even when considering only arm A versus arm B1, a pre-specified comparison in which all patients received the same conditioning regimen (Bu/Flu) and the same GVHD prophylaxis backbone regimen (Tac/Mtx), with the only difference being the addition of sirolimus in the experimental arm (Arm A). There was no difference in the rates of severe aGVHD, which were very low in both arms. This finding of a protective effect with sirolimus on aGVHD incidence should be broadly applicable to RIC HSCT, as there is no reason to believe or evidence to suggest that GVHD rates are different for patients with lymphoma than they are for patients with other haematological malignancies. Naturally, this benefit may only be extrapolated to T-cell-replete peripheral blood RIC HSCT. This stands in contrast to the results observed on BMT CTN 0402 (Cutler, et al 2012). Differences between these two randomized trials may be related to three factors: first, CTN 0402 only enrolled patients with MRDs; in the present trial, it is apparent that the absolute benefit of sirolimus for aGVHD prevention is greater for MUDs (although there was a trend towards benefit even in the MRD cohort, which may have reached significance with a larger sample size); second, CTN 0402 tested the substitution of sirolimus for methotrexate, whereas the present study tested the addition of sirolimus to a methotrexate-containing regimen; third, this was a trial in the RIC setting while CTN 0402 was performed in the myeloablative setting. Our results regarding aGVHD are very similar to those of the COG ASCT0431 trial, which had nearly identical GVHD prophylaxis regimens on both the experimental and control arms as those on the present trial (Pulsipher, et al 2014). In that study, the benefit of sirolimus for aGVHD control was offset by an increase in VOD; this difference between the arms was not observed on our study, probably because VOD is extremely rare in the RIC setting. Therefore, the aGVHD benefit may be achieved in RIC HSCT without an overall increase in other severe toxicities. Indeed, while there was an excess of grade 3-4 TMA-related toxicity with sirolimus on our study, the overall grade 3-4 toxicity was lower on the sirolimus arm; we hypothesize that this reflects the less frequent use of systemic corticosteroids in the sirolimus arm, consistent with the lower incidence of acute GVHD. Patients in both arms still suffered from a ~60% incidence of chronic GVHD,
which demands further research on newer regimens that may decrease this risk without elevating the risk of relapse. This trial did not use the consensus criteria for diagnosing and grading chronic GVHD (Filipovich, *et al* 2005). It is possible, though unlikely, that the incidence of cGVHD would be different with those criteria. Together, our findings suggest that Tac/Sir/Mtx is an acceptable regimen with T-cell-replete RIC HSCT, with no overall excess toxicity and a lower risk of non-severe aGVHD.

**ACKNOWLEDGMENTS**

P.A. was supported by an ASH Scholar Award, an ASCO Career Development Award, an ASBMT/Genentech Young Investigator Award, and a Dunkin Donuts Rising Star award for this work. This work was also supported by NIAID U19 AI 29530, NCI P01 CA142106, and the Jock and Bunny Adams Research and Education Endowment. We are also indebted to the nursing and research staff who were involved in this study, and to all of the participants and their families.

**REFERENCES**


Br J Haematol. Author manuscript; available in PMC 2017 April 01.


Figure 1. GVHD outcomes
(A) Grade 2-4 acute GVHD, stratified by arm; (B) Grade 3-4 acute GVHD, stratified by arm; (C) Grade 2-4 acute GVHD, stratified by arm and donor type; (D) Chronic GVHD.
GVHD, graft-versus-host disease; MUD, matched unrelated donor; MRD, matched related donor; Siro, sirolimus.
Figure 2. Survival outcomes
(A) Overall survival, stratified by arm; (B) Progression-free survival, stratified by arm; (C) Cumulative incidence of relapse/progression, stratified by arm; (D) Cumulative incidence of non-relapse mortality, stratified by arm; (E) Overall survival for patients with indolent B-cell non-Hodgkin lymphoma and Hodgkin lymphoma, stratified by arm; (F) Overall survival for patients with aggressive B-cell (including mantle cell) and T-cell non-Hodgkin lymphoma, stratified by arm. All analyses are on an intent-to-treat basis.
## Table I

### Baseline patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Arm A Tac/Sir/Mtx</th>
<th>Arm B Tac/Mtx or CSA/MMF</th>
<th>p value</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>66</td>
<td>73</td>
<td></td>
<td>139</td>
</tr>
<tr>
<td>Age, years; median, (range)</td>
<td>58 (23-70)</td>
<td>57 (23-69)</td>
<td>0.4</td>
<td>57 (23-70)</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indolent B-NHL</td>
<td>28 (42)</td>
<td>31 (42)</td>
<td>1.0</td>
<td>59 (42)</td>
</tr>
<tr>
<td>Aggressive B-NHL/MCL</td>
<td>20 (30)</td>
<td>23 (32)</td>
<td></td>
<td>43 (31)</td>
</tr>
<tr>
<td>T-NHL</td>
<td>8 (12)</td>
<td>10 (14)</td>
<td></td>
<td>18 (13)</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>10 (15)</td>
<td>9 (12)</td>
<td></td>
<td>19 (14)</td>
</tr>
<tr>
<td>Prior autologous transplant</td>
<td>34 (52)</td>
<td>31 (42)</td>
<td>0.3</td>
<td>65 (47)</td>
</tr>
<tr>
<td>Status at HSCT&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>34 (52)</td>
<td>32 (44)</td>
<td></td>
<td>66 (47)</td>
</tr>
<tr>
<td>PR</td>
<td>28 (42)</td>
<td>28 (38)</td>
<td></td>
<td>56 (40)</td>
</tr>
<tr>
<td>SD</td>
<td>2 (3)</td>
<td>9 (12)</td>
<td></td>
<td>11 (8)</td>
</tr>
<tr>
<td>PD</td>
<td>2 (3)</td>
<td>4 (5)</td>
<td></td>
<td>6 (4)</td>
</tr>
<tr>
<td>Donor</td>
<td></td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>MRD</td>
<td>27 (41)</td>
<td>29 (40)</td>
<td></td>
<td>56 (40)</td>
</tr>
<tr>
<td>MUD</td>
<td>39 (59)</td>
<td>44 (60)</td>
<td></td>
<td>83 (60)</td>
</tr>
<tr>
<td>Conditioning</td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Bu/Flu</td>
<td>63 (95)</td>
<td>69 (95)</td>
<td></td>
<td>130 (95)</td>
</tr>
<tr>
<td>Flu/Cy/TBI</td>
<td>3 (5)</td>
<td>4 (5)</td>
<td></td>
<td>7 (5)</td>
</tr>
<tr>
<td>GVHD prophylaxis</td>
<td></td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Tac/Sir/Mtx</td>
<td>66 (100)</td>
<td></td>
<td></td>
<td>66 (47)</td>
</tr>
<tr>
<td>Tac/Mtx</td>
<td></td>
<td>69 (95)</td>
<td></td>
<td>69 (50)</td>
</tr>
<tr>
<td>CSA/MMF</td>
<td>4 (5)</td>
<td></td>
<td></td>
<td>4 (3)</td>
</tr>
</tbody>
</table>

Tac/Sir/Mtx, Tacrolimus/Sirolimus/Methotrexate; CSA/MMF, ciclosporin/mycophenolate mofetil; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; HSCT, haematopoietic stem cell transplantation.

CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; MRD, matched related donor; MUD, matched unrelated donor; Bu/Flu, busulfan/fludarabine; Flu/Cy/TBI, fludarabine/cyclophosphamide/total body irradiation; GVHD, graft-versus-host disease; N/A, not applicable

<sup>a</sup>Percentages may not add to 100 because of rounding.

<sup>b</sup>Unknown for 2 patients.
Table II

Summary of toxicity.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Arm A (n=66 patients) Tac/Sir/Mtx</th>
<th>Arm B (n=73 patients) Tac/Mtx or CSA/MMF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3-4 Events&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TMA/renal failure/haemolysis</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>Leucopenia</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Infection</td>
<td>9</td>
<td>18</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Anorexia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Cataract</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Confusion/psychosis/encephalopathy</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Haematoma</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Respiratory</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Hepatic</td>
<td>4</td>
<td>15</td>
</tr>
<tr>
<td>Stomatitis/mucositis</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Weakness</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Allergic reaction</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Cardiac</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Dehydration</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Oedema</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Pain</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Hypomastia</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hypotension</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Rash</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

| Total grade 3-4 events                 | 128                               | 194                                      |

Events of interest given their possible association with sirolimus are bolded.

TMA, thrombotic microangiopathy

<sup>a</sup> Only events reported in >1 patient on at least one of the arms are listed.